EDIT icon

Editas Medicine

1.13 USD
-0.03
2.59%
At close Apr 1, 4:00 PM EDT
After hours
1.15
+0.02
1.77%
1 day
-2.59%
5 days
-13.74%
1 month
-36.16%
3 months
-13.74%
6 months
-65.44%
Year to date
-13.74%
1 year
-84.48%
5 years
-93.89%
10 years
-93.79%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

3% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 58

2% more call options, than puts

Call options by funds: $396K | Put options by funds: $388K

5.95% less ownership

Funds ownership: 67.78% [Q3] → 61.82% (-5.95%) [Q4]

11% less funds holding

Funds holding: 227 [Q3] → 203 (-24) [Q4]

34% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 58

66% less capital invested

Capital invested by funds: $190M [Q3] → $65.5M (-$125M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for EDIT.

Financial journalist opinion

Based on 7 articles about EDIT published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Editas Medicine Announces Chief Financial Officer Transition
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J.
Editas Medicine Announces Chief Financial Officer Transition
Neutral
Seeking Alpha
3 weeks ago
Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good morning, everyone. My name is Gena Wang, I'm [Indiscernible] at Biotech Analyst at the Barclays.
Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)
Neutral
Seeking Alpha
3 weeks ago
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Gilmore O'Neill - President & CEO Erick Lucera - EVP and CFO Unidentified Company Representative Welcome to Leerink Global Healthcare Conference 2025. So this morning, we are, discussing with the Editas Management Team, and we have Erick Lucera, and we have, Gilmore O'Neill with us.
Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)
Negative
Zacks Investment Research
3 weeks ago
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Negative
Zacks Investment Research
3 weeks ago
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.23 per share a year ago.
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
3 weeks ago
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-end On track to establish one additional target cell type/tissue by year-end Strong cash position with operational runway into the second quarter of 2027
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
Neutral
Seeking Alpha
4 weeks ago
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Editas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Alexander Kelly - TD Cowen Alexander Kelly Hi everyone. I'm Alex Kelly.
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript
Neutral
GlobeNewsWire
1 month ago
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
Neutral
Seeking Alpha
2 months ago
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided.
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Neutral
Seeking Alpha
2 months ago
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Linda Burkly - Executive Vice President and Chief Scientific Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Brian Cheng Good morning. Thanks for joining us for another session at the 43rd JPMorgan Healthcare Conference.
Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
Charts implemented using Lightweight Charts™